XOMA Corporation (XOMA) Rating Increased to Outperform at Wedbush
XOMA Corporation (NASDAQ:XOMA) was upgraded by analysts at Wedbush from a “neutral” rating to an “outperform” rating in a note issued to investors on Tuesday. The firm currently has a $19.00 price target on the biotechnology company’s stock, up from their prior price target of $9.00. Wedbush’s price target suggests a potential upside of 18.53% from the company’s current price.
A number of other equities research analysts have also weighed in on XOMA. HC Wainwright initiated coverage on XOMA Corporation in a research report on Monday, June 12th. They set a “buy” rating and a $15.00 price objective on the stock. ValuEngine upgraded XOMA Corporation from a “strong sell” rating to a “sell” rating in a research report on Wednesday, July 12th. Finally, Zacks Investment Research upgraded XOMA Corporation from a “hold” rating to a “buy” rating and set a $8.00 price objective on the stock in a research report on Friday, July 14th. One equities research analyst has rated the stock with a sell rating, three have given a hold rating and two have issued a buy rating to the stock. XOMA Corporation presently has a consensus rating of “Hold” and an average target price of $14.00.
XOMA Corporation (XOMA) opened at 16.03 on Tuesday. The stock has a 50 day moving average of $8.57 and a 200-day moving average of $6.96. XOMA Corporation has a one year low of $3.96 and a one year high of $16.73. The stock’s market cap is $121.80 million.
An institutional investor recently raised its position in XOMA Corporation stock. California Public Employees Retirement System raised its stake in XOMA Corporation (NASDAQ:XOMA) by 95.5% during the first quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 21,780 shares of the biotechnology company’s stock after buying an additional 10,640 shares during the period. California Public Employees Retirement System owned about 0.29% of XOMA Corporation worth $123,000 as of its most recent SEC filing. Hedge funds and other institutional investors own 32.92% of the company’s stock.
XOMA Corporation Company Profile
XOMA Corporation is a development-stage biotechnology company. The Company focuses on the discovery and development of monoclonal antibody-based therapeutics. It has five products in its endocrine portfolio, two of which are developed as part of its XOMA Metabolism (XMet) platform. Its products include XOMA 358, XOMA 129, XOMA 213 and Gevokizumab.
Receive News & Stock Ratings for XOMA Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for XOMA Corporation and related stocks with our FREE daily email newsletter.